Apr 24, 2024 / 01:00PM GMT
Anne Doering - Vivoryon Therapeutics NV - Chief Financial Officer
Good afternoon, everyone, and thank you for joining us today to discuss the company's full year 2023 results and strategic update conference call. This morning Vivoryon issued a press release reporting its full year 2023 financial results, including a strategic update, which is posted on the company's website at www.vivoryon.com.
Before we start, I would like to remind you that during this conference call, we will present and discuss certain forward-looking statements concerning the development of Vivoryon core platform.
The progress of its current research and development program and the initiation of additional programs as well as results of operation, cash needs, financial condition, liquidity, prospects, future transactions and strategies. Should actual results differ materially from the company's assumptions ensuing actions may differ from those anticipated. You are therefore cautioned not to place undue reliance on such forward-looking statements, which
Q4 2023 Vivoryon Therapeutics NV Earnings Call Transcript
Apr 25, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers